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D
iabetic ketoacidosis (DKA) and the
hyperosmolar hyperglycemic state
(HHS)arethetwomostseriousacute
metaboliccomplicationsofdiabetes.DKAis
responsibleformorethan500,000hospital
days per year (1,2) at an estimated annual
direct medical expense and indirect cost of
2.4 billion USD (2,3). Table 1 outlines the
diagnostic criteria for DKA and HHS. The
triad of uncontrolled hyperglycemia, meta-
bolic acidosis, and increased total body ke-
tone concentration characterizes DKA.
HHS is characterized by severe hyperglyce-
mia, hyperosmolality, and dehydration in
the absence of signiﬁcant ketoacidosis.
These metabolic derangements result from
the combination of absolute or relative
insulin deﬁciency and an increase in coun-
terregulatory hormones (glucagon, cat-
echolamines, cortisol, and growth
hormone). Most patients with DKA have
autoimmune type 1 diabetes; however, pa-
tients with type 2 diabetes are also at risk
during the catabolic stress of acute illness
such as trauma, surgery, or infections. This
consensusstatementwilloutlineprecipitat-
ingfactorsandrecommendationsforthedi-
agnosis, treatment, and prevention of DKA
and HHS in adult subjects. It is based on a
previous technical review (4) and more re-
cently published peer-reviewed articles
since 2001, which should be consulted for
further information.
EPIDEMIOLOGY— Recent epide-
miological studies indicate that hospital-
izations for DKA in the U.S. are
increasing. In the decade from 1996 to
2006, there was a 35% increase in the
number of cases, with a total of 136,510
cases with a primary diagnosis of DKA in
2006—a rate of increase perhaps more
rapid than the overall increase in the di-
agnosisofdiabetes(1).Mostpatientswith
DKA were between the ages of 18 and 44
years (56%) and 45 and 65 years (24%),
with only 18% of patients 20 years of
age. Two-thirds of DKA patients were
considered to have type 1 diabetes and
34% to have type 2 diabetes; 50% were
female, and 45% were nonwhite. DKA is
the most common cause of death in chil-
drenandadolescentswithtype1diabetes
and accounts for half of all deaths in dia-
betic patients younger than 24 years of
age (5,6). In adult subjects with DKA, the
overall mortality is 1% (1); however, a
mortality rate 5% has been reported in
the elderly and in patients with concom-
itant life-threatening illnesses (7,8).
Death in these conditions is rarely due to
the metabolic complications of hypergly-
cemia or ketoacidosis but relates to the
underlying precipitating illness (4,9).
Mortality attributed to HHS is consider-
ably higher than that attributed to DKA,
with recent mortality rates of 5–20%
(10,11).Theprognosisofbothconditions
is substantially worsened at the extremes
of age in the presence of coma, hypoten-
sion, and severe comorbidities (1,4,8,
12,13).
PATHOGENESIS— Theeventslead-
ingtohyperglycemiaandketoacidosisare
depicted in Fig. 1 (13). In DKA, reduced
effective insulin concentrations and in-
creased concentrations of counterregula-
tory hormones (catecholamines, cortisol,
glucagon, and growth hormone) lead to
hyperglycemia and ketosis. Hyperglyce-
mia develops as a result of three pro-
cesses: increased gluconeogenesis,
accelerated glycogenolysis, and impaired
glucose utilization by peripheral tissues
(12–17). This is magniﬁed by transient
insulinresistanceduetothehormoneim-
balance itself as well as the elevated free
fatty acid concentrations (4,18). The
combination of insulin deﬁciency and in-
creased counterregulatory hormones in
DKA also leads to the release of free fatty
acidsintothecirculationfromadiposetis-
sue(lipolysis)andtounrestrainedhepatic
fatty acid oxidation in the liver to ketone
bodies (-hydroxybutyrate and acetoace-
tate) (19), with resulting ketonemia and
metabolic acidosis.
Increasing evidence indicates that the
hyperglycemia in patients with hypergly-
cemic crises is associated with a severe
inﬂammatorystatecharacterizedbyanel-
evation of proinﬂammatory cytokines
(tumor necrosis factor- and interleu-
kin-, -6, and -8), C-reactive protein,
reactive oxygen species, and lipid peroxi-
dation, as well as cardiovascular risk fac-
tors, plasminogen activator inhibitor-1
and free fatty acids in the absence of ob-
vious infection or cardiovascular pathol-
ogy(20).Alloftheseparametersreturnto
near-normal values with insulin therapy
and hydration within 24 h. The proco-
agulant and inﬂammatory states may be
due to nonspeciﬁc phenomena of stress
and may partially explain the association
ofhyperglycemiccriseswithahypercoag-
ulable state (21).
The pathogenesis of HHS is not as
well understood as that of DKA, but a
greater degree of dehydration (due to os-
motic diuresis) and differences in insulin
availability distinguish it from DKA
(4,22). Although relative insulin deﬁ-
ciency is clearly present in HHS, endoge-
nous insulin secretion (reﬂected by
C-peptide levels) appears to be greater
than in DKA, where it is negligible (Table
2).InsulinlevelsinHHSareinadequateto
facilitate glucose utilization by insulin-
sensitive tissues but adequate to prevent li-
polysis and subsequent ketogenesis (12).
PRECIPITATING FACTORS— The
most common precipitating factor in the
development of DKA and HHS is infec-
tion (1,4,10). Other precipitating factors
include discontinuation of or inadequate
insulin therapy, pancreatitis, myocardial
infarction, cerebrovascular accident, and
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type 1 diabetes or discontinuation of in-
sulin in established type 1 diabetes com-
monly leads to the development of DKA.
In young patients with type 1 diabetes,
psychological problems complicated by
eating disorders may be a contributing
factor in 20% of recurrent ketoacidosis.
Factors that may lead to insulin omission
in younger patients include fear of weight
gain with improved metabolic control,
fear of hypoglycemia, rebellion against
authority, and stress of chronic disease.
Before 1993, the use of continuous
subcutaneous insulin infusion devices
had also been associated with an in-
creased frequency of DKA (23); however,
withimprovementintechnologyandbet-
ter education of patients, the incidence of
DKA appears to have reduced in pump
users. However, additional prospective
studies are needed to document reduc-
tionofDKAincidencewiththeuseofcon-
tinuous subcutaneous insulin infusion
devices (24).
Underlying medical illness that pro-
vokes the release of counterregulatory
hormones or compromises the access to
water is likely to result in severe dehydra-
tionandHHS.InmostpatientswithHHS,
restricted water intake is due to the pa-
tient being bedridden and is exacerbated
by the altered thirst response of the el-
derly. Because 20% of these patients have
no history of diabetes, delayed recogni-
tion of hyperglycemic symptoms may
have led to severe dehydration. Elderly
individualswithnew-onsetdiabetes(par-
ticularly residents of chronic care facili-
ties) or individuals with known diabetes
who become hyperglycemic and are un-
aware of it or are unable to take ﬂuids
when necessary are at risk for HHS
(10,25).
Drugs that affect carbohydrate metabo-
lism, such as corticosteroids, thiazides,
sympathomimetic agents, and pentami-
dine, may precipitate the development of
HHSorDKA(4).Recently,anumberofcase
reports indicate that the conventional anti-
psychotic as well as atypical antipsychotic
drugs may cause hyperglycemia and even
DKAorHHS(26,27).Possiblemechanisms
include the induction of peripheral insulin
resistance and the direct inﬂuence on pan-
creatic -cell function by 5-HT1A/2A/2C
receptor antagonism, by inhibitory effects
via 2-adrenergic receptors, or by toxic ef-
fects (28).
An increasing number of DKA cases
without precipitating cause have been re-
portedinchildren,adolescents,andadult
subjects with type 2 diabetes. Observa-
tional and prospective studies indicate
that over half of newly diagnosed adult
African American and Hispanic subjects
withunprovokedDKAhavetype2diabe-
tes (28–32). The clinical presentation in
such cases is acute (as in classical type 1
diabetes); however, after a short period of
insulin therapy, prolonged remission is
often possible, with eventual cessation of
insulintreatmentandmaintenanceofgly-
cemic control with diet or oral antihyper-
glycemic agents. In such patients, clinical
and metabolic features of type 2 diabetes
include a high rate of obesity, a strong
family history of diabetes, a measurable
pancreatic insulin reserve, a low preva-
lence of autoimmune markers of -cell
destruction,andtheabilitytodiscontinue
insulin therapy during follow-up (28,
31,32). This unique, transient insulin-
requiring proﬁle after DKA has been rec-
Figure1—PathogenesisofDKAandHHS:stress,infection,orinsufﬁcientinsulin.FFA,freefatty
acid.
Table 1—Diagnostic criteria for DKA and HHS
DKA HHS
Mild (plasma glucose
250 mg/dl)
Moderate (plasma glucose
250 mg/dl)
Severe (plasma glucose
250 mg/dl)
Plasma glucose
600 mg/dl
Arterial pH 7.25–7.30 7.00 to 7.24 7.00 7.30
Serum bicarbonate (mEq/l) 15–18 10 to 15 10 18
Urine ketone* Positive Positive Positive Small
Serum ketone* Positive Positive Positive Small
Effective serum osmolality† Variable Variable Variable 320 mOsm/kg
Anion gap‡ 10 12 12 Variable
Mental status Alert Alert/drowsy Stupor/coma Stupor/coma
*Nitroprusside reaction method. †Effective serum osmolality: 2measured Na
 (mEq/l)glucose (mg/dl)/18. ‡Anion gap: (Na
)  (Cl
  HCO3
 (mEq/l).
(Data adapted from ref. 13.)
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but has also been reported in Native
American, Asian, and white populations
(32). This variant of diabetes has been re-
ferred to in the literature as idiopathic
type 1 diabetes, atypical diabetes, “Flat-
bush diabetes,” type 1.5 diabetes, and
more recently, ketosis-prone type 2 dia-
betes.Someexperimentalworkhassheda
mechanistic light on the pathogenesis of
ketosis-prone type 2 diabetes. At presen-
tation, they have markedly impaired in-
sulin secretion and insulin action, but
aggressive management with insulin im-
provesinsulinsecretionandactiontolev-
els similar to those of patients with type 2
diabetes without DKA (28,31,32). Re-
cently, it has been reported that the near-
normoglycemic remission is associated
with a greater recovery of basal and stim-
ulated insulin secretion and that 10 years
after diabetes onset, 40% of patients are
still non–insulin dependent (31). Fasting
C-peptide levels of 1.0 ng/dl (0.33
nmol/l) and stimulated C-peptide levels
1.5 ng/dl (0.5 nmol/l) are predictive of
long-term normoglycemic remission in
patients with a history of DKA (28,32).
DIAGNOSIS
History and physical examination
The process of HHS usually evolves over
several days to weeks, whereas the evolu-
tion of the acute DKA episode in type 1
diabetes or even in type 2 diabetes tends
to be much shorter. Although the symp-
tomsofpoorlycontrolleddiabetesmaybe
present for several days, the metabolic al-
terations typical of ketoacidosis usually
evolvewithinashorttimeframe(typically
24 h). Occasionally, the entire symp-
tomatic presentation may evolve or de-
velop more acutely, and the patient may
present with DKA with no prior clues or
symptoms. For both DKA and HHS, the
classicalclinicalpictureincludesahistory
of polyuria, polydipsia, weight loss, vom-
iting, dehydration, weakness, and mental
status change. Physical ﬁndings may in-
clude poor skin turgor, Kussmaul respi-
rations (in DKA), tachycardia, and
hypotension. Mental status can vary from
full alertness to profound lethargy or
coma, with the latter more frequent in
HHS.Focalneurologicsigns(hemianopia
and hemiparesis) and seizures (focal or
generalized) may also be features of HHS
(4,10). Although infection is a common
precipitating factor for both DKA and
HHS, patients can be normothermic or
even hypothermic primarily because of
peripheral vasodilation. Severe hypother-
mia, if present, is a poor prognostic sign
(33). Nausea, vomiting, diffuse abdomi-
nalpainarefrequentinpatientswithDKA
(50%) but are uncommon in HHS (33).
Caution needs to be taken with patients
who complain of abdominal pain on pre-
sentation because the symptoms could be
either a result of the DKA or an indication
of a precipitating cause of DKA, particu-
larlyinyoungerpatientsorintheabsence
of severe metabolic acidosis (34,35). Fur-
ther evaluation is necessary if this com-
plaint does not resolve with resolution of
dehydration and metabolic acidosis.
Laboratory ﬁndings
The diagnostic criteria for DKA and HHS
are shown in Table 1. The initial labora-
tory evaluation of patients include deter-
mination of plasma glucose, blood urea
nitrogen, creatinine, electrolytes (with
calculated anion gap), osmolality, serum
and urinary ketones, and urinalysis, as
well as initial arterial blood gases and a
complete blood count with a differential.
An electrocardiogram, chest X-ray, and
urine, sputum, or blood cultures should
also be obtained.
The severity of DKA is classiﬁed as
mild, moderate, or severe based on the
severity of metabolic acidosis (blood pH,
bicarbonate, and ketones) and the pres-
ence of altered mental status (4). Signiﬁ-
cant overlap between DKA and HHS has
been reported in more than one-third of
patients (36). Although most patients
with HHS have an admission pH 7.30
and a bicarbonate level 18 mEq/l, mild
ketonemia may be present (4,10).
Severe hyperglycemia and dehydra-
tion with altered mental status in the ab-
sence of signiﬁcant acidosis characterize
HHS, which clinically presents with less
ketosis and greater hyperglycemia than
DKA. This may result from a plasma in-
sulin concentration (as determined by
baseline and stimulated C-peptide [Table
2])adequatetopreventexcessivelipolysis
and subsequent ketogenesis but not hy-
perglycemia (4).
The key diagnostic feature in DKA is
theelevationincirculatingtotalbloodke-
tone concentration. Assessment of aug-
mented ketonemia is usually performed
by the nitroprusside reaction, which pro-
vides a semiquantitative estimation of
acetoacetate and acetone levels. Although
the nitroprusside test (both in urine and
inserum)ishighlysensitive,itcanunder-
estimate the severity of ketoacidosis be-
cause this assay does not recognize the
presence of -hydroxybutyrate, the main
metabolic product in ketoacidosis (4,12).
If available, measurement of serum -
hydroxybutyrate may be useful for diag-
nosis (37). Accumulation of ketoacids
results in an increased anion gap meta-
Table 2—Admission biochemical data in patients with HHS or DKA
HHS DKA
Glucose (mg/dl) 930 	 83 616 	 36
Na
 (mEq/l) 149 	 3.2 134 	 1.0
K
 (mEq/l) 3.9 	 0.2 4.5 	 0.13
BUN (mg/dl) 61 	 11 32 	 3
Creatinine (mg/dl) 1.4 	 0.1 1.1 	 0.1
pH 7.3 	 0.03 7.12 	 0.04
Bicarbonate (mEq/l) 18 	 1.1 9.4 	 1.4
3--hydroxybutyrate (mmol/l) 1.0 	 0.2 9.1 	 0.85
Total osmolality* 380 	 5.7 323 	 2.5
IRI (nmol/l) 0.08 	 0.01 0.07 	 0.01
C-peptide (nmol/l) 1.14 	 0.1 0.21 	 0.03
Free fatty acids (nmol/l) 1.5 	 0.19 1.6 	 0.16
Human growth hormone (ng/ml) 1.9 	 0.2 6.1 	 1.2
Cortisol (ng/ml) 570 	 49 500 	 61
IRI (nmol/l)† 0.27 	 0.05 0.09 	 0.01
C-peptide (nmol/l)† 1.75 	 0.23 0.25 	 0.05
Glucagon (ng/ml) 689 	 215 580 	 147
Catacholamines (ng/ml) 0.28 	 0.09 1.78 	 0.4
Growth hormone (ng/ml) 1.1 7.9

Gap: anion gap  12 (mEq/l) 11 17
*According to the formula 2(Na  K)  urea (mmol/l)  glucose (mmol/l). †Values following intravenous
administration of tolbutamide. IRI, immunoreactive insulin. (Adapted from ref. 4.)
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by subtracting the sum of chloride and
bicarbonate concentration from the so-
dium concentration: [Na  (Cl 
HCO3)].Anormalaniongapisbetween7
and 9 mEq/l and an anion gap 10–12
mEq/l indicate the presence of increased
anion gap metabolic acidosis (4).
Hyperglycemiaisakeydiagnosticcri-
terion of DKA; however, a wide range of
plasma glucose can be present on admis-
sion. Elegant studies on hepatic glucose
production rates have reported rates
ranging from normal or near normal (38)
to elevated (12,15), possibly contributing
to the wide range of plasma glucose levels
in DKA that are independent of the sever-
ity of ketoacidosis (37). Approximately
10%oftheDKApopulationpresentswith
so-called “euglycemic DKA”—glucose
levels 250 mg/dl (38). This could be
due to a combination of factors, including
exogenous insulin injection en route to the
hospital, antecedent food restriction (39,
40), and inhibition of gluconeogenesis.
On admission, leukocytosis with cell
counts in the 10,000–15,000 mm
3 range
is the rule in DKA and may not be indic-
ative of an infectious process. However,
leukocytosis with cell counts 25,000
mm
3 may designate infection and require
further evaluation (41). In ketoacidosis,
leukocytosis is attributed to stress and
maybecorrelatedtoelevatedlevelsofcor-
tisol and norepinephrine (42). The ad-
mission serum sodium is usually low
because of the osmotic ﬂux of water from
the intracellular to the extracellular space
in the presence of hyperglycemia. An in-
creased or even normal serum sodium
concentration in the presence of hyper-
glycemia indicates a rather profound de-
gree of free water loss. To assess the
severity of sodium and water deﬁcit, se-
rum sodium may be corrected by adding
1.6 mg/dl to the measured serum sodium
for each 100 mg/dl of glucose above 100
mg/dl (4,12).
Studies on serum osmolality and
mental alteration have established a posi-
tive linear relationship between osmolal-
ity and mental obtundation (9,36). The
occurrenceofstupororcomainadiabetic
patient in the absence of deﬁnitive eleva-
tionofeffectiveosmolality(320mOsm/
kg) demands immediate consideration of
other causes of mental status change. In
thecalculationofeffectiveosmolality,[so-
dium ion (mEq/l)  2  glucose (mg/dl)/
18], the urea concentration is not taken
intoaccountbecauseitisfreelypermeable
and its accumulation does not induce
major changes in intracellular volume
or osmotic gradient across the cell
membrane (4).
Serum potassium concentration may
be elevated because of an extracellular
shift of potassium caused by insulin deﬁ-
ciency, hypertonicity, and acidemia (43).
Patients with low normal or low serum
potassium concentration on admission
have severe total-body potassium deﬁ-
ciency and require careful cardiac moni-
toring and more vigorous potassium
replacement because treatment lowers
potassium further and can provoke car-
diacdysrhythmia.Pseudonormoglycemia
(44) and pseudohyponatremia (45) may
occur in DKA in the presence of severe
chylomicronemia.
Theadmissionserumphosphatelevel
in patients with DKA, like serum potas-
sium, is usually elevated and does not re-
ﬂect an actual body deﬁcit that uniformly
exists due to shifts of intracellular phos-
phate to the extracellular space (12,
46,47). Insulin deﬁciency, hypertonicity,
andincreasedcatabolismallcontributeto
the movement of phosphate out of cells.
Hyperamylasemia has been reported
in 21–79% of patients with DKA (48);
however, there is little correlation be-
tween the presence, degree, or isoenzyme
type of hyperamylasemia and the pres-
ence of gastrointestinal symptoms (nau-
sea, vomiting, and abdominal pain) or
pancreatic imaging studies (48). A serum
lipase determination may be beneﬁcial in
the differential diagnosis of pancreatitis;
however, lipase could also be elevated in
DKA in the absence of pancreatitis (48).
Differential diagnosis
Not all patients with ketoacidosis have
DKA. Starvation ketosis and alcoholic ke-
toacidosis are distinguished by clinical
history and by plasma glucose concentra-
tions that range from mildly elevated
(rarely 200 mg/dl) to hypoglycemia
(49). In addition, although alcoholic ke-
toacidosiscanresultinprofoundacidosis,
the serum bicarbonate concentration in
starvation ketosis is usually not 18
mEq/l. DKA must also be distinguished
from other causes of high–anion gap met-
abolic acidosis, including lactic acidosis;
ingestion of drugs such as salicylate,
methanol, ethylene glycol, and paralde-
hyde; and acute chronic renal failure (4).
Because lactic acidosis is more common
in patients with diabetes than in nondia-
betic persons and because elevated lactic
acid levels may occur in severely volume-
contractedpatients,plasmalactateshould
be measured on admission.
A clinical history of previous drug
abuse should be sought. Measurement of
serumsalicylateandbloodmethanollevel
may be helpful. Ethylene glycol (anti-
freeze)issuggestedbythepresenceofcal-
ciumoxalateandhippuratecrystalsinthe
urine. Paraldehyde ingestion is indicated
by its characteristic strong odor on the
breath.Becausetheseintoxicantsarelow–
molecular weight organic compounds,
they can produce an osmolar gap in addi-
tion to the anion gap acidosis (14). A re-
centreportstatesthatactivecocaineuseis
an independent risk factor for recurrent
DKA (50).
Recently, one case report has shown
that a patient with diagnosed acromegaly
may present with DKA as the primary
manifestation of the disease (51). In addi-
tion, an earlier report of pituitary gigan-
tism was presented with two episodes of
DKAwithcompleteresolutionofdiabetes
after pituitary apoplexy (52).
TREATMENT— Successfultreatment
of DKA and HHS requires correction of
dehydration, hyperglycemia, and electro-
lyte imbalances; identiﬁcation of comor-
bid precipitating events; and above all,
frequent patient monitoring. Protocols
for the management of patients with DKA
and HHS are summarized in Fig. 2 (52).
Fluid therapy
Initial ﬂuid therapy is directed toward ex-
pansion of the intravascular, interstitial,
and intracellular volume, all of which are
reduced in hyperglycemic crises (53) and
restoration of renal perfusion. In the ab-
sence of cardiac compromise, isotonic sa-
line (0.9% NaCl) is infused at a rate of
15–20 ml   kg body wt
1   h
1 or 1–1.5 l
during the ﬁrst hour. Subsequent choice
for ﬂuid replacement depends on hemo-
dynamics, the state of hydration, serum
electrolyte levels, and urinary output. In
general, 0.45% NaCl infused at 250–500
ml/h is appropriate if the corrected serum
sodium is normal or elevated; 0.9% NaCl
at a similar rate is appropriate if corrected
serum sodium is low (Fig. 2). Successful
progress with ﬂuid replacement is judged
by hemodynamic monitoring (improve-
ment in blood pressure), measurement of
ﬂuidinput/output,laboratoryvalues,and
clinical examination. Fluid replacement
should correct estimated deﬁcits within
the ﬁrst 24 h. In patients with renal or
cardiac compromise, monitoring of se-
rum osmolality and frequent assessment
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beperformedduringﬂuidresuscitationto
avoid iatrogenic ﬂuid overload (4,10,
15,53). Aggressive rehydration with sub-
sequent correction of the hyperosmolar
state has been shown to result in a more
robust response to low-dose insulin ther-
apy (54).
During treatment of DKA, hypergly-
cemia is corrected faster than ketoacido-
sis. The mean duration of treatment until
blood glucose is 250 mg/dl and ketoac-
idosis (pH 7.30; bicarbonate 18
mmol/l)iscorrectedis6and12h,respec-
tively (9,55). Once the plasma glucose
is  200 mg/dl, 5% dextrose should be
added to replacement ﬂuids to allow con-
tinued insulin administration until ke-
tonemia is controlled while at the same
time avoiding hypoglycemia.
Insulin therapy
The mainstay in the treatment of DKA in-
volves the administration of regular insu-
linviacontinuousintravenousinfusionor
by frequent subcutaneous or intramuscu-
lar injections (4,56,57). Randomized
controlled studies in patients with DKA
have shown that insulin therapy is effec-
tive regardless of the route of administra-
tion (47). The administration of
continuous intravenous infusion of regu-
lar insulin is the preferred route because
of its short half-life and easy titration and
thedelayedonsetofactionandprolonged
half-life of subcutaneous regular insulin
(36,47,58).
Numerous prospective randomized
studies have demonstrated that use of
low-dose regular insulin by intravenous
infusion is sufﬁcient for successful recov-
ery of patients with DKA. Until recently,
treatment algorithms recommended the
administration of an initial intravenous
dose of regular insulin (0.1 units/kg) fol-
lowed by the infusion of 0.1 units   kg
1  
h
1 insulin (Fig. 2). A recent prospective
randomized study reported that a bolus
dose of insulin is not necessary if patients
receive an hourly insulin infusion of 0.14
units/kgbodywt(equivalentto10units/h
in a 70-kg patient) (59). In the absence of
an initial bolus, however, doses 0.1
units   kg
1   h
1 resulted in a lower in-
sulin concentration, which may not be
adequatetosuppresshepaticketonebody
production without supplemental doses
of insulin (15).
Low-dose insulin infusion protocols
decrease plasma glucose concentration at
a rate of 50–75 mg   dl
1   h
1. If plasma
glucose does not decrease by 50–75 mg
from the initial value in the ﬁrst hour, the
insulin infusion should be increased ev-
ery hour until a steady glucose decline is
achieved (Fig. 2). When the plasma glu-
cose reaches 200 mg/dl in DKA or 300
mg/dl in HHS, it may be possible to de-
crease the insulin infusion rate to 0.02–
0.05 units   kg
1   h
1, at which time
dextrosemaybeaddedtotheintravenous
ﬂuids (Fig. 2). Thereafter, the rate of in-
Figure 2—Protocol for management of adult patients with DKA or HHS. DKA diagnostic criteria: blood glucose 250 mg/dl, arterial pH 7.3,
bicarbonate 15 mEq/l, and moderate ketonuria or ketonemia. HHS diagnostic criteria: serum glucose 600 mg/dl, arterial pH 7.3, serum
bicarbonate 15 mEq/l, and minimal ketonuria and ketonemia. †15–20 ml/kg/h; ‡serum Na should be corrected for hyperglycemia (for each 100
mg/dl glucose 100 mg/dl, add 1.6 mEq to sodium value for corrected serum value). (Adapted from ref. 13.) Bwt, body weight; IV, intravenous; SC,
subcutaneous.
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of dextrose may need to be adjusted to
maintain glucose values between 150 and
200 mg/dl in DKA or 250 and 300 mg/dl
in HHS until they are resolved.
Treatment with subcutaneous rapid-
acting insulin analogs (lispro and aspart)
has been shown to be an effective alterna-
tive to the use of intravenous regular in-
sulin in the treatment of DKA. Treatment
of patients with mild and moderate DKA
with subcutaneous rapid-acting insulin
analogs every 1 or2hi nnon–intensive
care unit (ICU) settings has been shown
to be as safe and effective as the treatment
with intravenous regular insulin in the
ICU (60,61). The rate of decline of blood
glucose concentration and the mean du-
ration of treatment until correction of ke-
toacidosis were similar among patients
treated with subcutaneous insulin ana-
logs every 1 or2ho rwith intravenous
regular insulin. However, until these
studies are conﬁrmed outside the re-
search arena, patients with severe DKA,
hypotension, anasarca, or associated se-
verecriticalillnessshouldbemanagedwith
intravenous regular insulin in the ICU.
Potassium
Despite total-body potassium depletion,
mild-to-moderate hyperkalemia is com-
mon in patients with hyperglycemic cri-
ses. Insulin therapy, correction of
acidosis, and volume expansion decrease
serum potassium concentration. To pre-
vent hypokalemia, potassium replace-
ment is initiated after serum levels fall
below the upper level of normal for the
particular laboratory (5.0–5.2 mEq/l).
The treatment goal is to maintain serum
potassium levels within the normal range
of 4–5 mEq/l. Generally, 20–30 mEq po-
tassium in each liter of infusion ﬂuid is
sufﬁcient to maintain a serum potassium
concentration within the normal range.
Rarely, DKA patients may present with
signiﬁcant hypokalemia. In such cases,
potassiumreplacementshouldbeginwith
ﬂuid therapy, and insulin treatment
should be delayed until potassium con-
centration is restored to 3.3 mEq/l to
avoidlife-threateningarrhythmiasandre-
spiratory muscle weakness (4,13).
Bicarbonate therapy
The use of bicarbonate in DKA is contro-
versial (62) because most experts believe
that during the treatment, as ketone bod-
ies decrease there will be adequate bicar-
bonate except in severely acidotic
patients. Severe metabolic acidosis can
lead to impaired myocardial contractility,
cerebral vasodilatation and coma, and
several gastrointestinal complications
(63). A prospective randomized study in
21patientsfailedtoshoweitherbeneﬁcial
or deleterious changes in morbidity or
mortality with bicarbonate therapy in
DKA patients with an admission arterial
pH between 6.9 and 7.1 (64). Nine small
studies in a total of 434 patients with di-
abetic ketoacidosis (217 treated with bi-
carbonate and 178 patients without alkali
therapy [62]) support the notion that bi-
carbonate therapy for DKA offers no ad-
vantage in improving cardiac or
neurologic functions or in the rate of re-
covery of hyperglycemia and ketoacido-
sis. Moreover, several deleterious effects
of bicarbonate therapy have been re-
ported, such as increased risk of hypoka-
lemia, decreased tissue oxygen uptake
(65), cerebral edema (65), and develop-
ment of paradoxical central nervous sys-
tem acidosis.
No prospective randomized studies
concerningtheuseofbicarbonateinDKA
with pH values 6.9 have been reported
(66). Because severe acidosis may lead to
a numerous adverse vascular effects (63),
it is recommended that adult patients
withapH6.9shouldreceive100mmol
sodiumbicarbonate(twoampules)in400
ml sterile water (an isotonic solution)
with20mEqKCIadministeredatarateof
200 ml/h for 2 h until the venous pH is
7.0. If the pH is still 7.0 after this is
infused, we recommend repeating infusion
every 2 h until pH reaches 7.0 (Fig. 2).
Phosphate
Despite whole-body phosphate deﬁcits in
DKA that average 1.0 mmol/kg body wt,
serum phosphate is often normal or in-
creased at presentation. Phosphate con-
centrationdecreaseswithinsulintherapy.
Prospective randomized studies have
failed to show any beneﬁcial effect of
phosphate replacement on the clinical
outcome in DKA (46,67), and overzeal-
ous phosphate therapy can cause severe
hypocalcemia (46,68). However, to avoid
potential cardiac and skeletal muscle
weakness and respiratory depression due
to hypophosphatemia, careful phosphate
replacement may sometimes be indicated
in patients with cardiac dysfunction, ane-
mia, or respiratory depression and in
those with serum phosphate concentra-
tion 1.0 mg/dl (4,12). When needed,
20–30 mEq/l potassium phosphate can
be added to replacement ﬂuids. The max-
imal rate of phosphate replacement gen-
erally regarded as safe to treat severe
hypophosphatemia is 4.5 mmol/h (1.5
ml/hofK2PO4)(69).Nostudiesareavail-
able on the use of phosphate in the treat-
ment of HHS.
Transition to subcutaneous insulin
Patients with DKA and HHS should be
treated with continuous intravenous
insulin until the hyperglycemic crisis is
resolved. Criteria for resolution of
ketoacidosis include a blood glucose
200 mg/dl and two of the following cri-
teria: a serum bicarbonate level 15
mEq/l, a venous pH 7.3, and a calcu-
lated anion gap12 mEq/l. Resolution of
HHS is associated with normal osmolality
andregainofnormalmentalstatus.When
thisoccurs,subcutaneousinsulintherapy
can be started. To prevent recurrence of
hyperglycemia or ketoacidosis during the
transitionperiodtosubcutaneousinsulin,
it is important to allow an overlap of 1–2
hbetweendiscontinuationofintravenous
insulin and the administration of subcu-
taneous insulin. If the patient is to remain
fasting/nothing by mouth, it is preferable
to continue the intravenous insulin infu-
sion and ﬂuid replacement. Patients with
known diabetes may be given insulin at
the dosage they were receiving before the
onset of DKA so long as it was controlling
glucose properly. In insulin-naïve pa-
tients, a multidose insulin regimen
should be started at a dose of 0.5–0.8
units   kg
1   day
1 (13). Human insulin
(NPH and regular) are usually given in
twoorthreedosesperday.Morerecently,
basal-bolus regimens with basal (glargine
and detemir) and rapid-acting insulin an-
alogs (lispro, aspart, or glulisine) have
been proposed as a more physiologic in-
sulin regimen in patients with type 1 dia-
betes. A prospective randomized trial
compared treatment with a basal-bolus
regimen, including glargine once daily
and glulisine before meals, with a split-
mixed regimen of NPH plus regular insu-
lin twice daily following the resolution of
DKA. Transition to subcutaneous
glargine and glulisine resulted in similar
glycemic control compared with NPH
and regular insulin; however, treatment
with basal bolus was associated with a
lower rate of hypoglycemic events (15%)
than the rate in those treated with NPH
and regular insulin (41%) (55).
Complications
Hypoglycemia and hypokalemia are two
common complications with overzealous
treatment of DKA with insulin and bicar-
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tions have occurred less often with the
low-dose insulin therapy (4,56,57). Fre-
quent blood glucose monitoring (every
1–2 h) is mandatory to recognize hypo-
glycemia because many patients with
DKA who develop hypoglycemia during
treatment do not experience adrenergic
manifestations of sweating, nervousness,
fatigue, hunger, and tachycardia. Hyper-
chloremicnon–aniongapacidosis,which
is seen during the recovery phase of DKA,
is self-limited with few clinical conse-
quences (43). This may be caused by loss
of ketoanions, which are metabolized to
bicarbonate during the evolution of DKA
and excess ﬂuid infusion of chloride con-
taining ﬂuids during treatment (4).
Cerebral edema, which occurs in
0.3–1.0% of DKA episodes in children,
is extremely rare in adult patients during
treatment of DKA. Cerebral edema is as-
sociated with a mortality rate of 20–40%
(5) and accounts for 57–87% of all DKA
deaths in children (70,71). Symptoms
and signs of cerebral edema are variable
and include onset of headache, gradual
deterioration in level of consciousness,
seizures, sphincter incontinence, pupil-
lary changes, papilledema, bradycardia,
elevation in blood pressure, and respira-
toryarrest(71).Anumberofmechanisms
have been proposed, which include the
role of cerebral ischemia/hypoxia, the
generationofvariousinﬂammatorymedi-
ators (72), increased cerebral blood ﬂow,
disruption of cell membrane ion trans-
port, and a rapid shift in extracellular and
intracellular ﬂuids resulting in changes in
osmolality. Prevention might include
avoidance of excessive hydration and
rapid reduction of plasma osmolarity, a
gradual decrease in serum glucose, and
maintenance of serum glucose between
250–300 mg/dl until the patient’s serum
osmolality is normalized and mental sta-
tusisimproved.Manitolinfusionandme-
chanical ventilation are suggested for
treatment of cerebral edema (73).
PREVENTION— ManycasesofDKA
and HHS can be prevented by better ac-
cess to medical care, proper patient edu-
cation, and effective communication with
a health care provider during an intercur-
rent illness. Paramount in this effort is
improved education regarding sick
day management, which includes the
following:
1) Early contact with the health care
provider.
2) Emphasizing the importance of in-
sulin during an illness and the reasons
never to discontinue without contacting
the health care team.
3) Review of blood glucose goals and
the use of supplemental short- or rapid-
acting insulin.
4) Having medications available to
suppress a fever and treat an infection.
5)Initiationofaneasilydigestibleliq-
uiddietcontainingcarbohydratesandsalt
when nauseated.
6) Education of family members on
sick day management and record keeping
including assessing and documenting
temperature, blood glucose, and urine/
blood ketone testing; insulin administra-
tion; oral intake; and weight. Similarly,
adequate supervision and staff education
in long-term facilities may prevent many
of the admissions for HHS due to dehy-
dration among elderly individuals who
areunabletorecognizeortreatthisevolv-
ing condition.
The use of home glucose-ketone
meters may allow early recognition of im-
pending ketoacidosis, which may help to
guide insulin therapy at home and, possi-
bly,maypreventhospitalizationforDKA.
In addition, home blood ketone monitor-
ing, which measures -hydroxybutyrate
levels on a ﬁngerstick blood specimen, is
now commercially available (37).
The observation that stopping insulin
for economic reasons is a common pre-
cipitant of DKA (74,75) underscores the
need for our health care delivery systems
to address this problem, which is costly
and clinically serious. The rate of insulin
discontinuation and a history of poor
complianceaccountsformorethanhalfof
DKA admissions in inner-city and minor-
itypopulations(9,74,75).Severalcultural
and socioeconomic barriers, such as low
literacy rate, limited ﬁnancial resources,
and limited access to health care, in med-
ically indigent patients may explain the
lack of compliance and why DKA contin-
ues to occur in such high rates in inner-
city patients. These ﬁndings suggest that
the current mode of providing patient ed-
ucation and health care has signiﬁcant
limitations. Addressing health problems
in the African American and other minor-
itycommunitiesrequiresexplicitrecogni-
tion of the fact that these populations are
probably quite diverse in their behavioral
responses to diabetes (76).
Signiﬁcant resources are spent on the
costofhospitalization.DKAepisodesrep-
resent 1 of every 4 USD spent on direct
medicalcareforadultpatientswithtype1
diabetes and 1 of every 2 USD in patients
experiencing multiple episodes (77).
Based on an annual average of 135,000
hospitalizations for DKA in the U.S., with
an average cost of 17,500 USD per pa-
tient, the annual hospital cost for patients
withDKAmayexceed2.4billionUSDper
year (3). A recent study (2) reported that
the cost burden resulting from avoidable
hospitalizationsduetoshort-termuncon-
trolled diabetes including DKA is sub-
stantial (2.8 billion USD). However, the
long-term impact of uncontrolled diabe-
tes and its economic burden could be
moresigniﬁcantbecauseitcancontribute
to various complications. Because most
casesoccurinpatientswithknowndiabe-
tes and with previous DKA, resources
need to be redirected toward prevention
by funding better access to care and edu-
cational programs tailored to individual
needs, including ethnic and personal
health care beliefs. In addition, resources
should be directed toward the education
of primary care providers and school per-
sonnel so that they can identify signs and
symptoms of uncontrolled diabetes and
so that new-onset diabetes can be diag-
nosed at an earlier time. Recent studies
suggest that any type of education for nu-
trition has resulted in reduced hospital-
ization (78). In fact, the guidelines for
diabetesself-managementeducationwere
developed by a recent task force to iden-
tify ten detailed standards for diabetes
self-management education (79).
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